SCHEMBL16294307

SCHEMBL16294307

COc1nnc(Cl)c2ccc(Br)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
PTGES O14684 2/20 0.37
PRNP P04156 1/20 0.35
PDE5A O76074 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HTT P42858 1/20 0.33
ATM Q13315 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
GOT1 P17174 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16295195 0.93 ALDH1A1 (0.47) ALDH1A1CYP1A2CYP2C19PTGESPRNP
SCHEMBL29426545 0.81 HTT (0.41) ALDH1A1CYP1A2CYP2C19PRNPMEN1
SCHEMBL2459267 0.81 HTT (0.41) ALDH1A1CYP1A2CYP2C19PRNPMEN1
SCHEMBL27002448 0.77 ALDH1A1 (0.48) ALDH1A1CYP1A2CYP2C19PTGESPRNP
SCHEMBL25843042 0.77 CYP1A2 (0.41) ALDH1A1CYP1A2CYP2C19PRNPMEN1
SCHEMBL30462715 0.77 CYP1A2 (0.41) ALDH1A1CYP1A2CYP2C19PRNPMEN1
SCHEMBL6939619 0.76 ALDH1A1 (0.75) ALDH1A1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL4998018 0.74 CA1 (0.44) ALDH1A1CYP1A2CYP2C19LMNAHTT
SCHEMBL23087369 0.74 PTGES (0.46) ALDH1A1PTGESMEN1KMT2ALMNA
SCHEMBL29735237 0.74 PTGES (0.46) ALDH1A1PTGESMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776995-B2 Bicyclic sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-10-03 US disclosed
US-9776995-B2 Bicyclic sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-10-03 US disclosed
US-9776995-B2 Bicyclic sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-10-03 US disclosed
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors AMGEN INC. 2016-05-19 US disclosed
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors AMGEN INC. 2016-05-19 US disclosed
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors AMGEN INC. 2016-05-19 US disclosed
WO-2014201173-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. (US) 2014-12-18 WO disclosed
WO-2014201173-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. (US) 2014-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137636-A1 Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors SCN7A, SCN1A, SCN5A ALDH1A1 1463/4885CYP1A2 1678/4885CYP2C19 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.